Paper35359702
Can anti-parasitic drugs help control COVID-19?
Panahi Y and 7 others. Future Virol, 2022. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Can anti-parasitic drugs help control COVID-19? Papers, record 35359702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35359702
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References194
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25108173 | Nitazoxanide: a first-in-class broad-spectrum antiviral agent. | Antiviral Res | 2014 | https://conductscience.org/library/papers/25108173 | PubMed |
| 2 | 17314215 | Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. | Rheumatology (Oxford) | 2007 | https://conductscience.org/library/papers/17314215 | PubMed |
| 3 | 32378705 | A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. | Biosci Rep | 2020 | https://conductscience.org/library/papers/32378705 | PubMed |
| 4 | 32075877 | Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. | Science | 2020 | https://conductscience.org/library/papers/32075877 | PubMed |
| 5 | 31320117 | Advancing Drug Discovery via Artificial Intelligence. | Trends Pharmacol Sci | 2019 | https://conductscience.org/library/papers/31320117 | PubMed |
| 6 | 32735799 | Roles of flavonoids against coronavirus infection. | Chem Biol Interact | 2020 | https://conductscience.org/library/papers/32735799 | PubMed |
| 7 | 16122816 | Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. | Antiviral Res | 2005 | https://conductscience.org/library/papers/16122816 | PubMed |
| 8 | 32275497 | Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. | Emerg Infect Dis | 2020 | https://conductscience.org/library/papers/32275497 | PubMed |
| 9 | 32271460 | Coronavirus disease 2019: a bibliometric analysis and review. | Eur Rev Med Pharmacol Sci | 2020 | https://conductscience.org/library/papers/32271460 | PubMed |
| 10 | 33264556 | Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33264556 | PubMed |
| 11 | 32409561 | Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. | BMJ | 2020 | https://conductscience.org/library/papers/32409561 | PubMed |
| 12 | 32125140 | Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. | ACS Infect Dis | 2020 | https://conductscience.org/library/papers/32125140 | PubMed |
| 13 | 32247927 | Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. | Travel Med Infect Dis | 2020 | https://conductscience.org/library/papers/32247927 | PubMed |
| 14 | 33300221 | Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. | Int J Clin Pract | 2021 | https://conductscience.org/library/papers/33300221 | PubMed |
| 15 | 33815126 | Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33815126 | PubMed |
| 16 | 33170521 | Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach. | Drug Dev Res | 2021 | https://conductscience.org/library/papers/33170521 | PubMed |
| 17 | 33590901 | Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. | J Med Virol | 2021 | https://conductscience.org/library/papers/33590901 | PubMed |
| 18 | 32407884 | QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. | Heart Rhythm | 2020 | https://conductscience.org/library/papers/32407884 | PubMed |
| 19 | 25730813 | Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. | Pak J Pharm Sci | 2015 | https://conductscience.org/library/papers/25730813 | PubMed |
| 20 | 11727315 | Computational methods to estimate drug development parameters. | Curr Opin Drug Discov Devel | 2001 | https://conductscience.org/library/papers/11727315 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38980578 | Exploring COVID-19 Pandemic Disparities with Transcriptomic Meta-analysis from the Perspective of Personalized Medicine. | J Microbiol | 2024 | https://conductscience.org/library/papers/38980578 | PubMed |
| 37375747 | Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37375747 | PubMed |
| 36915278 | A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease? | Future Virol | 2023 | https://conductscience.org/library/papers/36915278 | PubMed |
| 36116513 | Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches. | Chem Biol Interact | 2022 | https://conductscience.org/library/papers/36116513 | PubMed |
| 35744958 | Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment? | Molecules | 2022 | https://conductscience.org/library/papers/35744958 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35359702
GET https://conductscience.org/api/papers/v1/35359702/references?page=2